Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
← catalyst calendarNCT06258668 · readout in 773 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
505estimated
Sites
2
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-21 | actual | When the study began enrolling |
| Primary completion | 2028-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate-to-severe Plaque Psoriasis
Intervention
- Drug: Deucravacitinib
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 24 weeks from treatment initiation
Number of participants with adverse drug reactions (ADRs)
measured Up to 24 weeks from treatment initiation
Number of participants with serious adverse events (SAEs)
measured Up to 24 weeks from treatment initiation
Number of participants with serious adverse drug reactions (SADRs)
measured Up to 24 weeks from treatment initiation
Number of participants with unexpected adverse events (AEs)
measured Up to 24 weeks from treatment initiation
Number of participants with unexpected adverse drug reactions (ADRs)
measured Up to 24 weeks from treatment initiation
Number of participants with unexpected serious adverse events (SAEs)
measured Up to 24 weeks from treatment initiation
Number of participants with unexpected serious adverse drug reactions (SADRs)
measured Up to 24 weeks from treatment initiation
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed